SCHEMBL6154983

SCHEMBL6154983

NC(=O)c1ccc(NCCN2CCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 1/20 0.49
EPHX2 P34913 1/20 0.49
ESR1 P03372 1/20 0.48
ESR2 Q92731 1/20 0.48
ESRRG P62508 2/20 0.48
ALDH1A1 P00352 3/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CNR1 P21554 1/20 0.47
POLB P06746 2/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
HTR7 P34969 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30969317 0.98 TNIK (0.51) TNIKEPHX2ESR1ESR2ESRRG
SCHEMBL30969280 0.91 HTR7 (0.53) EPHX2KDM4EHTR7HRH3
SCHEMBL30969324 0.88 HDAC6 (0.52) ALDH1A1CNR1POLBMEN1KMT2A
SCHEMBL3222256 0.87 EPHX2 (0.54) EPHX2ALDH1A1CNR1POLBKDM4E
SCHEMBL5350540 0.86 ESRRG (0.52) EPHX2ESR1ESR2ESRRGALDH1A1
SCHEMBL1068474 0.84 ESRRG (0.54) EPHX2ESR1ESR2ESRRGALDH1A1
SCHEMBL4685953 0.81 HRH3 (0.60) TNIKCYP2C9MEN1KMT2AHPGD
SCHEMBL30969330 0.81 ALDH1A1 (0.71) EPHX2ALDH1A1NPSR1CYP1A2CYP2D6
SCHEMBL29605727 0.80 CYP1A2 (0.74) EPHX2ALDH1A1NPSR1CYP1A2CYP2D6
SCHEMBL3234486 0.79 KDM4E (0.61) ALDH1A1CYP2D6CYP2C9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642766-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-11-05 EP disclosed
WO-2024145585-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-07-04 WO disclosed
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 TNIK 1662/4885EPHX2 1186/4885ESR1 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.